Simple once-daily treatment

Symptoms illustrated. Not an actual patient.

Not a steroid. No boxed warning

Before & After

RELIABLE RESULTS ANYWHERE ON THE BODY

RELIEF PATIENTS CAN SEE AND FEEL

Review clinical trial photos of patients with atopic dermatitis treated with ZORYVE

RELIEF PATIENTS CAN SEE AND FEEL

Review clinical trial photos of patients with atopic dermatitis treated with ZORYVE

Popliteal Fossa2

AGE 32, FEMALE

Actual clinical trial patient

Popliteal Fossa with atopic dermatitis before treatment - Baseline vIGA-AD = 3

Baseline vIGA-AD=3

Actual clinical trial patient

Popliteal Fossa with atopic dermatitis on Week 1 of treatment - vIGA-AD = 2
Popliteal Fossa with atopic dermatitis on Week 4 of treatment - vIGA-AD = 1

Mouth2

AGE 9, FEMALE

Actual clinical trial patient

Mouth with atopic dermatitis before treatment - Baseline vIGA-AD = 3

Baseline vIGA-AD=3

Actual clinical trial patient

Mouth with atopic dermatitis on Week 1 of treatment - vIGA-AD = 1
Mouth with atopic dermatitis on Week 4 of treatment - vIGA-AD = 0

Hand2

AGE 11, FEMALE

Actual clinical trial patient

Hand with atopic dermatitis before treatment - Baseline vIGA-AD = 3

Baseline vIGA-AD=3

Actual clinical trial patient

Hand with atopic dermatitis on Week 1 of treatment - vIGA-AD = 2
Hand with atopic dermatitis on Week 4 of treatment - vIGA-AD = 1

Neck2

AGE 51, MALE

Actual clinical trial patient

Neck with atopic dermatitis before treatment - Baseline vIGA-AD = 3

Baseline vIGA-AD=3

Actual clinical trial patient

Neck with atopic dermatitis on Week 1 of treatment - vIGA-AD = 2
Neck with atopic dermatitis on Week 4 of treatment - vIGA-AD = 1

Trunk2

AGE 22, MALE

Actual clinical trial patient

Trunk with atopic dermatitis before treatment - Baseline vIGA-AD = 3

Baseline vIGA-AD=3

Actual clinical trial patient

Trunk with atopic dermatitis on Week 1 of treatment - vIGA-AD = 2
Trunk with atopic dermatitis on Week 4 of treatment - vIGA-AD = 1

Wrist2

AGE 16, FEMALE

Actual clinical trial patient

Wrist with atopic dermatitis before treatment - Baseline vIGA-AD = 3

Baseline vIGA-AD=3

Actual clinical trial patient

Wrist with atopic dermatitis on Week 1 of treatment - vIGA-AD = 2
Wrist with atopic dermatitis on Week 4 of treatment - vIGA-AD = 0

vIGA-AD = Validated Investigator Global Assessment-Atopic Dermatitis. vIGA-AD Scale: 4 = Severe, 3 = Moderate, 2 = Mild, 1 = Almost Clear, 0 = Clear